Related Experiment Video

Updated: May 14, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells

Jin Sun Lee1, In Sang Yoon, Myung Sun Lee

  • 1Department of Surgery, Chungnam National University Hospital, Daejeon 301–721, Korea.

Biological & Pharmaceutical Bulletin
|February 2, 2013
PubMed

Insights

Pristimerin, a natural compound, inhibits HER2-positive breast cancer cell growth by downregulating HER2 and fatty acid synthase (FASN). It also modulates key signaling pathways, impacting metastasis and inducing apoptosis, suggesting potential as a chemotherapeutic agent.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Pristimerin is a natural triterpenoid exhibiting cytotoxicity against various cancer cell lines.
  • The precise mechanism underlying pristimerin's cytotoxic effects remains largely unelucidated.
  • Targeting the human epidermal growth factor receptor 2 (HER2) is a validated strategy in breast cancer therapy.

Purpose of the Study:

  • To investigate the cytotoxic effects of pristimerin on HER2-positive SKBR3 human breast cancer cells.
  • To elucidate the molecular mechanisms by which pristimerin exerts its anti-cancer effects.
  • To evaluate pristimerin's potential as a chemotherapeutic agent for HER2-positive breast cancers.

Main Methods:

  • Cell proliferation assays were performed to assess dose- and time-dependent effects.
  • Quantitative PCR and Western blotting were used to measure HER2 and FASN expression and activity.
  • Analysis of Akt, MAPK, and mTOR signaling pathway phosphorylation levels.
  • Cell migration, invasion, apoptosis assays (Western blotting, flow cytometry).

Main Results:

  • Pristimerin significantly inhibited SKBR3 cell proliferation in a dose- and time-dependent manner.
  • Pristimerin downregulated both HER2 protein and mRNA expression.
  • Pristimerin reduced Fatty Acid Synthase (FASN) expression and activity, with exogenous palmitate partially rescuing proliferation.
  • Pristimerin modulated Akt, MAPK (Erk1/2, p38, JNK), and mTOR signaling pathways, inhibiting cell migration, invasion, and inducing apoptosis via caspase activation.

Conclusions:

  • Pristimerin demonstrates novel HER2-downregulating activity in HER2-positive breast cancer cells.
  • Pristimerin exerts anti-cancer effects by decreasing FASN, modulating critical signaling pathways (Akt, MAPK, mTOR), and inhibiting metastasis.
  • Pristimerin induces apoptosis and shows promise as a potential chemotherapeutic agent for HER2-positive breast cancers.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...